84 results
424B5
IMNM
Immunome Inc
14 May 24
Prospectus supplement for primary offering
8:48am
believe that the pursuit of novel or underexplored targets will be central to the next generation of transformative therapies, and we are dedicated … -in-class targeted cancer therapies. We select our targets with a modality appropriate to its biology, including antibody-drug conjugates, or ADCs
8-K
EX-99.1
IMNM
Immunome Inc
14 May 24
Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
8:02am
, including small molecules, ADCs, and RLTs. We believe that pursuing underexplored targets with appropriate drug modalities leads to transformative … and targets.
For more information, visit www.immunome.com or follow us on Twitter and LinkedIn.
Cautionary Statement Regarding Forward-Looking Statements
S-3ASR
IMNM
Immunome Inc
3 Apr 24
Automatic shelf registration
4:40pm
of novel or underexplored targets will be central to the next generation of transformative therapies. For that reason, we pursue therapeutics that we … and develop a broad pipeline of ADCs, as different targets may require different payloads to achieve optimal efficacy and therapeutic index. The novel
S-3ASR
quzbgp1k s7h
3 Apr 24
Automatic shelf registration
4:36pm
8-K
EX-99.1
td7dqmamts4s6
28 Mar 24
Immunome Reports Full-Year 2023 Financial Results and Provides Update on Recently Acquired Assets
4:04pm
8-K
EX-10.1
5rsw9hlzsbod03wrf6
26 Mar 24
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
8:05am
8-K
EX-99.1
p837qn7ev
26 Mar 24
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
8:05am
424B5
tai6n67tie fkoers
14 Feb 24
Prospectus supplement for primary offering
4:09pm
424B5
y0839l 6w9
13 Feb 24
Prospectus supplement for primary offering
4:36pm
8-K
EX-99.1
wm1b3ra q00v1l
13 Feb 24
Results of Operations and Financial Condition
4:10pm
8-K
EX-99.2
r9u nkbog
13 Feb 24
Results of Operations and Financial Condition
4:10pm
S-3ASR
b6oxfmmyqacz8
13 Feb 24
Automatic shelf registration
4:04pm
8-K
EX-99.1
4pw bjo2mku0w
6 Feb 24
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
8:05am
8-K
EX-2.1
hu8kdpgrim2oz8am03
6 Feb 24
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
8:05am
8-K
EX-99.1
ktnznuqd5yri
11 Jan 24
Regulation FD Disclosure
5:27pm